INCB-099280
- Generic Name
- INCB-099280
Pre-Transplant INCBB099280 for Hepatocellular Carcinoma (HCC)
- First Posted Date
- 2024-03-29
- Last Posted Date
- 2024-08-09
- Lead Sponsor
- Abramson Cancer Center at Penn Medicine
- Registration Number
- NCT06337162
- Locations
- 🇺🇸
Abramson Cancer Center at University of Pennsylvania, Philadelphia, Pennsylvania, United States
A Study Assessing the Mass Balance, Pharmacokinetics, and Metabolite Profiles of a Single Oral Dose of [14C]INCB099280 in Healthy Male Participants
- First Posted Date
- 2024-03-13
- Last Posted Date
- 2024-06-13
- Lead Sponsor
- Incyte Corporation
- Target Recruit Count
- 5
- Registration Number
- NCT06309394
- Locations
- 🇬🇧
Quotient Sciences Ltd, Nottingham, United Kingdom
A Study of INCB099280 in Combination With Adagrasib in Adults With Advanced Solid Tumors Harboring a KRASG12C Mutation
- Conditions
- Advanced Solid Tumors
- Interventions
- First Posted Date
- 2023-09-15
- Last Posted Date
- 2025-05-02
- Lead Sponsor
- Incyte Corporation
- Target Recruit Count
- 6
- Registration Number
- NCT06039384
- Locations
- 🇮🇹
Fondazione Del Piemonte Per L Oncologia Ircc Candiolo, Candiolo, Italy
🇺🇸Valkyrie Clinical Trials, Los Angeles, California, United States
🇺🇸Banner Md Anderson Cancer Center, Greeley, Colorado, United States
A Study of INCB099280 in Combination With Axitinib in Adults With Advanced Solid Tumors
- Conditions
- Advanced Solid Tumors
- Interventions
- First Posted Date
- 2023-07-18
- Last Posted Date
- 2025-05-13
- Lead Sponsor
- Incyte Corporation
- Target Recruit Count
- 5
- Registration Number
- NCT05949632
- Locations
- 🇬🇧
Beatson West of Scotland Cancer Centrewester, Glasgow, United Kingdom
🇬🇧Addenbrookes Hospital, Cambridge, United Kingdom
🇬🇧St Bartholomew'S Hospital, London, United Kingdom
A Study to Evaluate INCB099280 in Participants With Advanced Cutaneous Squamous Cell Carcinoma
- Conditions
- Cutaneous Squamous Cell Carcinoma
- Interventions
- First Posted Date
- 2023-06-05
- Last Posted Date
- 2025-01-07
- Lead Sponsor
- Incyte Corporation
- Target Recruit Count
- 63
- Registration Number
- NCT05888844
- Locations
- 🇫🇷
Hopital Charles Nicolle Chu Rouen Hospital de Bois-Guillaume, Rouen Cedex, France
🇫🇷Centre Hospitalier de Pau - Hôpital François Mitterrand, Pau Cedex, France
🇫🇷University Hospital of Saint Etienne, Saint Etienne Cedex 2, France
A Study to Evaluate INCB099280 in Participants With Select Solid Tumors Who Are Immune Checkpoint Inhibitor Naive
- First Posted Date
- 2023-05-30
- Last Posted Date
- 2025-02-04
- Lead Sponsor
- Incyte Corporation
- Target Recruit Count
- 73
- Registration Number
- NCT05879822
- Locations
- 🇧🇷
Fundacao Pio Xii Hospital de Cancer de Barretos, Barretos, Brazil
🇧🇷Cionc-Centro Integrado de Oncologia de Curitiba, Curitiba, Brazil
🇧🇷Oncosite - Centro de Pesquisa Clinica E Oncologia, Ijui, Brazil
Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of INCB099280 in Participants With Advanced Solid Tumors
- Conditions
- Cutaneous Squamous Cell CarcinomaHepatoCellular CarcinomaMesotheliomaAdvanced Solid TumorMSI-H/dMMR TumorsUrothelial CarcinomaEsophageal Squamous Cell CarcinomaSmall-cell Lung CancerCervical CancerMerkel Cell Carcinoma
- Interventions
- First Posted Date
- 2020-01-27
- Last Posted Date
- 2025-01-10
- Lead Sponsor
- Incyte Corporation
- Target Recruit Count
- 182
- Registration Number
- NCT04242199
- Locations
- 🇺🇸
Upmc Cancercenter, Pittsburgh, Pennsylvania, United States
🇦🇺Chris Obrien Lifehouse, Camperdown, New South Wales, Australia
🇺🇸Md Anderson Cancer Center, Houston, Texas, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.